Corbus Pharmaceuticals Holdings Inc
(NASDAQ : CRBP)

( )
CRBP PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Are you a Dividend Trader
Learn how to make passive income from the best dividend stocks.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
AMGNAmgen Inc.
0.38%194.911.2%$602.16m
GILDGilead Sciences, Inc.
-0.78%67.480.9%$499.30m
CELGCelgene Corporation
-0.19%69.271.2%$492.42m
BIIBBiogen Inc.
0.01%319.251.3%$467.66m
ILMNIllumina, Inc.
-5.73%301.593.5%$381.70m
REGNRegeneron Pharmaceuticals, Inc.
0.00%338.982.6%$298.66m
VRTXVertex Pharmaceuticals Incorporated
-2.45%161.071.9%$260.54m
ALXNAlexion Pharmaceuticals, Inc.
-3.00%115.062.0%$199.08m
AAgilent Technologies, Inc.
-3.72%62.571.5%$185.86m
SRPTSarepta Therapeutics, Inc.
-2.25%116.3615.4%$146.77m
LGNDLigand Pharmaceuticals Incorporated
-3.83%148.5423.3%$139.57m
EXASExact Sciences Corporation
0.00%67.2825.3%$137.02m
NKTRNektar Therapeutics
-0.58%38.015.6%$122.24m
INCYIncyte Corporation
-3.40%64.252.5%$115.74m
TSROTESARO, Inc.
-0.41%36.6814.4%$108.95m

Company Profile

Corbus Pharmaceuticals Holdings, Inc. is a phase 3 clinical-stage pharmaceutical company, focused on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. The Company's lead product candidate, lenabasum, is a novel, synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and fibrotic processes. Lenabasum is currently being evaluated in systemic sclerosis, cystic fibrosis, dermatomyositis, and systemic lupus erythematosus. The company was founded in December 2013 and is headquartered in Norwood, MA.